Charles E. Binkley, MD, Michael S. Politz, MA, and Brian P. Green, PhD
If the safe-and-effective standard for judging devices’ potential as therapy or enhancement is inadequate, one might wonder whether BCI regulation should be overseen by the FDA.
AMA J Ethics. 2021;23(9):E745-749. doi:
10.1001/amajethics.2021.745.
Dr Charles Binkley joins Ethics Talk to discuss his article, coauthored with Michael Politz and Dr Brian Green: "Who, If Not the FDA, Should Regulate Implantable Brain-Computer Interface Devices?"
Laura N. Gitlin, PhD and Nancy A. Hodgson, PhD, RN
As a matter of medical ethics, physicians must address the health care needs of and be advocates for family caregivers of their patients with dementia.
AMA J Ethics. 2016;18(12):1171-1181. doi:
10.1001/journalofethics.2016.18.12.ecas1-1612.
B. Rashmi Borah, Nicolle K. Strand, JD, MBioethics, and Kata L. Chillag, PhD
The Bioethics Commission’s recommendations to include research participants with impaired consent capacity provide an ethical foundation for neuroscience.
AMA J Ethics. 2016;18(12):1192-1198. doi:
10.1001/journalofethics.2016.18.12.nlit1-1612.